亚治疗剂量华法林逆转后脑出血结局:GWTG-Stroke分析
基于GWTG-Stroke登记2015年1月至2022年1月的观察性队列,纳入1868例正在服用华法林、INR 1.5-1.9的自发性脑出血患者,比较逆转治疗与未逆转的结局。逆转组出院mRS 0-3比例无显著改善(aOR 0.80,95%CI 0.63-1.005),但院内死亡或出院至临终关怀风险降低25%(aOR 0.75,95%CI 0.63-0.89),住院时间更长。
要点
- INR 1.5-1.9的华法林相关脑出血逆转后功能结局无显著改善。
- 逆转组院内死亡或出院至临终关怀风险降低25%。
- 逆转组住院时间更长,静脉血栓栓塞无显著差异。
核心结论
- 亚治疗剂量华法林(INR 1.5-1.9)相关自发性脑出血逆转治疗与出院mRS 0-3无显著改善相关。
- 逆转组院内死亡或出院至临终关怀的 odds 降低25%,但住院时间更长。
研究设计与样本
- GWTG-Stroke登记2015年1月至2022年1月的观察性队列,最终纳入1868例当前使用华法林、INR 1.5-1.9的自发性脑出血患者。
- 采用logistic回归评估逆转与出院mRS 0-3的关联,并用倾向评分重叠加权控制治疗选择偏倚。
- 排除接受溶栓、直接口服抗凝药、转出或违背医嘱离院的患者;逆转剂剂量与时机信息未知。
主要发现
- 主要结局出院mRS 0-3在逆转组为188/894(21.0%),未逆转组为225/974(23.1%),aOR 0.80(95%CI 0.63-1.005)。
- 序贯分析显示mRS 0-4 versus 5-6的 odds 更高(52.7% versus 42.5%,aOR 1.21,95%CI 1.001-1.48)。
- 不依赖mRS的结局在2569例中分析:院内死亡或出院至临终关怀30.6% versus 41.5%(aOR 0.75,95%CI 0.63-0.89)。
- 住院时间中位数6天 versus 4天(调整风险比1.25,95%CI 1.13-1.37);静脉血栓栓塞无差异(2.9% versus 2.3%,aOR 1.47,95%CI 0.88-2.46)。
关键数值与推荐
- 亚治疗剂量定义为INR 1.5-1.9,纳入要求当前使用华法林。
- 主要结局为出院时mRS 0-3;探索性分析终点包括院内死亡或出院至临终关怀、住院时间及静脉血栓栓塞。
临床怎么用
- 对INR 1.5-1.9的华法林相关脑出血,逆转治疗可能降低院内死亡或出院至临终关怀风险,但功能结局获益不明确。
- 临床决策需权衡死亡风险降低与住院时间延长,并考虑本研究为非随机试验的探索性证据。
局限性
- 为观察性登记研究而非随机对照试验,存在固有局限。
- 逆转剂的剂量与时机信息未知,可能影响结果解释。
- 主要功能结局aOR的95%CI上限接近1.0,统计学不确定性较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines recommend reversal of warfarin anticoagulation in intracranial hemorrhages. The benefit of reversing subtherapeutic warfarin anticoagulation in acute spontaneous intracerebral hemorrhage is uncertain. METHODS: An observational cohort from the entire Get With The Guidelines Stroke registry between January 2015 and January 2022 was used to determine the association of reversal with outcomes for subtherapeutic anticoagulation (international normalized ratio, 1.5-1.9). Inclusion required current warfarin use. Exclusions included thrombolytics, direct oral anticoagulants, transferring out, or leaving against medical advice. The prespecified primary outcome was the modified Rankin Scale (mRS) score of 0 to 3 at discharge. Logistic regression was used to assess the association between reversal and the mRS score of 0 to 3. Propensity scores with overlap weighting were used to control treatment selection bias. Information on the dose and timing of reversal agents was unknown. RESULTS: Initial cohort 239 681 patients, 18 419 on warfarin. Excluded were 15 712 with an international normalized ratio ≤1.5, ≥1.9, or missing, and 701 missing mRS. Final cohort 1868 (mean age 73, 42% female). Reversal occurred in 894 (47.9%). Primary outcome occurred in 188/894 (21.0%) versus 225/974 (23.1%) with reversal versus without (adjusted odds ratio, 0.80 [95% CI, 0.63-1.005]). Ordinal analysis showed higher odds of mRS score of 0 to 4 versus 5 to 6 (52.7% versus 42.5% [adjusted odds ratio, 1.21 [1.001-1.48]). Outcomes not requiring mRS were analyzed among 2569 patients. Mortality or discharge to hospice was lower 30.6% versus 41.5% (adjusted odds ratio, 0.75 [95% CI, 0.63-0.89]). Hospital length of stay was longer (median, 6 versus 4 days; adjusted risk ratio, 1.25 [95% CI, 1.13-1.37]). There was no difference in venous thromboembolism (2.9% versus 2.3%; adjusted odds ratio, 1.47 [0.88-2.46]). CONCLUSIONS: Reversal of subtherapeutic warfarin with acute spontaneous intracerebral hemorrhage and international normalized ratio 1.5 to 1.9 was not associated with improvement in functional outcome based on discharge mRS score of 0 to 3 versus 4 to 6. Patients receiving reversal agents had 25% lower odds of dying in hospital or being discharged to hospice, but had a longer hospital stay. This exploratory data has limitations inherent to not being a randomized controlled trial.
引用
- LacKamp AN, Weber JM, Mac Grory B, et al. Intracerebral Hemorrhage Outcomes After Reversal of Subtherapeutic Warfarin: Analysis of Data From GWTG-Stroke. Stroke. 2025. PMID: 40959900. doi:10.1161/STROKEAHA.124.050281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。